

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 47/18	A1	(11) International Publication Number: WO 97/23239 (43) International Publication Date: 3 July 1997 (03.07.97)
<p>(21) International Application Number: PCT/JP96/03772</p> <p>(22) International Filing Date: 25 December 1996 (25.12.96)</p> <p>(30) Priority Data: 7/336714 25 December 1995 (25.12.95) JP</p> <p>(71) Applicant (for all designated States except US): OTSUKA PHARMACEUTICAL CO., LTD. [JP/JP]; 9, Kandatsukasa-cho 2-chome, Chiyoda-ku, Tokyo 101 (JP).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): YAMASHITA, Chikamasa [JP/JP]; 11-4, Nishinokoshi, Tokunagakawamukai, Otsu-cho, Naruto-shi, Tokushima 772 (JP). SAKATA, Kazuya [JP/JP]; 117-1, Aza Kaya, Tainohama, Kitajima-cho, Itano-gun, Tokushima 771-02 (JP). ISHIKAWA, Shinichi [JP/JP]; 5-7, Hiyoshidai 1-chome, Otsu-shi, Shiga 520-01 (JP). KIMURA, Yuzo [JP/JP]; 4-33-10, Minamishomachi, Tokushima-shi, Tokushima 770 (JP).</p> <p>(74) Agents: SAEGUSA, Eiji et al.; Kitahama TNK Building, 1-7-1, Dosho-machi, Chuo-ku, Osaka-shi, Osaka 541 (JP).</p>		<p>(81) Designated States: AU, BR, CA, CN, KR, MX, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(54) Title: DRY COMPOSITIONS</p> <p>(57) Abstract</p> <p>The object of the present invention is to provide a dry composition having the following advantageous properties. That is, even when left in a highly humid environment, the dry composition of the present invention scarcely loses its pharmacological activity, does not deliquesce and retains its dry state over a long period of time. A dry composition of the present invention comprises at least one of active ingredients selected from the group consisting of pharmacologically active proteins and pharmacologically active polypeptides and as a stabilizer at least one of hydrophobic stabilizers selected from the group consisting of hydrophobic amino acids, hydrophobic dipeptides and hydrophobic tripeptides.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

-1-

DRY COMPOSITIONS

Technical Field

The present invention relates to a dry composition.

5

Background Art

Heretofore, several publications have disclosed dry compositions comprising at least one of active ingredients selected from the group consisting of pharmacologically active proteins and pharmacologically active polypeptides in combination with a stabilizer therefor, including human serum albumin, saccharides such as sucrose, mannitol or the like and amino acids such as glycine, alanine, phenylalanine, glutamic acid or the like. (Japanese Unexamined Patent Publication No. 102519/1980, European Patent Publication No. 80879A, European Patent Publication No. 82481A, Japanese Unexamined Patent Publication No. 181224/1984, European Patent Publication No. 133767A, European Patent Publication No. 401379A and European Patent Publication No. 168008A). Of those relevant prior arts, the techniques disclosed in Japanese Unexamined Patent Publication No. 102519/1980, European Patent Publication No. 82481A, Japanese Unexamined Patent Publication No. 181224/1984 and European Patent Publication No. 168008A

-2-

are similar to that of the present invention.

Japanese Unexamined Patent Publication No. 102519/1980 discloses the method in which any one of polyethylene-based nonionic surfactant, antibiotic, 5 chelating agent and aromatic amine is added to an aqueous solution containing interferon and subjected to lyophilization so as to stabilize interferon.

European Patent Publication No. 82481A discloses a lyophilized pharmaceutical composition 10 comprising interferon, an amino acid or the derivative thereof selected from glycine, α -alanine and pharmaceutical acceptable salts thereof in an amount sufficient to stabilize interferon, and a buffer compatible therewith.

15 Japanese Unexamined Patent Publication No. 181224/1984 discloses a pharmaceutical preparation containing interferon obtained by adding an amino acid or an amino acid and human serum albumin to an aqueous solution containing interferon, followed by 20 lyophilization. Useful amino acids specified in this publication are hydrophilic polar amino acids, such as arginine, asparagine, glutamic acid, glutamine, histidine, lysine, serine and threonine. The publication describes that of those amino acids, glutamic acid is 25 particularly preferred.

-3-

European Patent Publication No. 168008A

discloses a composition comprising human γ interferon
obtained by conducting freezing or lyophilization under
the conditions where inorganic salts are substantially
5 absent but amino acids are present. This publication
describes that useful amino acids are monoamino aliphatic
amino acids. However, the amino acid employed in the
examples of this publication is glycine only, and no
other amino acids than glycine is employed.

10 The objects of the above patent applications
are all to provide lyophilized pharmaceutical
preparations stable enough to be used in the form of
injections.

However, the dry compositions disclosed in the
15 above publications have the following serious drawbacks.
For example, when the dry composition is left in a highly
humid environment, the active ingredient contained in the
composition loses its effectiveness and the composition
does not retain its dry state due to deliquescence,
20 thereby causing a change in appearance. Further, when
the dry composition is preserved in a bottle covered with
a rubber stopper without strictly controlling the dryness
of the rubber stopper, the dry composition deliquesces
due to the moisture contained in the rubber stopper and
25 the active ingredient suffers deterioration in its

-4-

pharmacological activity. Moreover, in the case where the dry composition in the form of particles is produced by conducting spray-drying from a solution containing the above active ingredient and the stabilizer, as well as in
5 the case where the above solution is subjected to lyophilization followed by milling, the size of the individual grains varies greatly and hence it is difficult for the final product to secure uniformity. In particular, since the obtained product necessarily
10 includes granules of a large particle size and the particle size increases in a highly humid environment, it is difficult to administer this product by an intrapulmonary route or an intrapharynx route.

Disclosure of the Invention

15 In view of the foregoing, the inventors conducted extensive research to develop a dry composition free from the drawbacks described above. Consequently, the inventors found that an advantageous dry composition in which the above drawbacks are overcome can be obtained
20 by employing the following specific substances as the stabilizer for the active ingredient in the dry composition. The present invention is accomplished based on the finding.

The present invention relates to a dry
25 composition comprising at least one of active ingredients

-5-

selected from the group consisting of pharmacologically active proteins and pharmacologically active polypeptides and as a stabilizer at least one of hydrophobic stabilizers selected from the group consisting of hydrophobic amino acids, hydrophobic dipeptides and hydrophobic tripeptides.

In accordance with the present invention, there is provided a dry composition free from the conventional drawbacks described above. For example, even when the dry composition is left in a highly humid environment, the active ingredient contained in the dry composition scarcely loses its pharmacological activity and the dry composition does not deliquesce and retains its dry state over a long period of time. Further, in the case where the dry composition in the form of particles is produced from a solution containing the above active ingredient and the stabilizer by performing spray-drying, and in the case where the solution containing the above active ingredient and the stabilizer is subjected to lyophilization followed by milling, desired particles can be obtained whose particle size distribution is sharp enough to be suitably administered by an intrapulmonary route or an intrapharynx route. Moreover, the stabilizers employed in the present invention are inexpensive, readily available and industrially

-6-

advantageous.

The dry compositions according to the present invention encompass the following compositions:

(1) A dry composition comprising at least one
5 of active ingredients selected from the group consisting
of pharmacologically active proteins and
pharmacologically active polypeptides and as a stabilizer
at least one of hydrophobic stabilizers selected the
group consisting of hydrophobic amino acids, hydrophobic
10 dipeptides and hydrophobic tripeptides having a
Hydropathy Index of at least about 3.

(2) A dry composition as defined in Item (1) in
which the stabilizer is a hydrophobic stabilizer having a
Hydropathy Index ranging from about 3.8 to about 4.5.

15 (3) A dry composition as defined in Item (2)
in which the stabilizer is valine.

(4) A dry composition as defined in Item (2)
in which the stabilizer is leucine.

(5) A dry composition as defined in Item (2)
20 in which the stabilizer is isoleucine.

(6) A dry composition as defined in Item (2)
in which the active ingredient is interferon.

(7) A dry composition as defined in Item (6)
in which the stabilizer is a hydrophobic amino acid.

25 (8) A dry composition as defined in Item (7)

-7-

in which the active ingredient is interferon- α .

(9) A dry composition as defined in Item (2)

in which the active ingredient is interleukin.

(10) A dry composition as defined in Item (9)

5 in which the stabilizer is a hydrophobic amino acid.

(11) A dry composition as defined in Item (1)

in which the particle size is in the range of from 0.1 μm
to 10 μm .

(12) A dry composition as defined in Item (11)

10 in which the stabilizer is a hydrophobic stabilizer
having a Hydropathy Index ranging from about 3.8 to about
4.5.

(13) A dry composition as defined in Item (12)

in which the stabilizer is a hydrophobic amino acid.

15 (14) A dry composition as defined in Item (13)

in which the stabilizer is valine.

(15) A dry composition as defined in Item (13)

in which the stabilizer is leucine.

(16) A dry composition as defined in Item (13)

20 in which the stabilizer is isoleucine.

(17) A dry composition as defined in Item (12)

in which the active ingredient is interferon.

(18) A dry composition as defined in Item (17)

in which the stabilizer is a hydrophobic amino acid.

25 (19) A dry composition as defined in Item (18)

-8-

in which the stabilizer is valine.

(20) A dry composition as defined in Item (18)
in which the stabilizer is leucine.

(21) A dry composition as defined in Item (18)
5 in which the stabilizer is isoleucine.

(22) A dry composition as defined in Item (12)
in which the active ingredient is interleukin.

(23) A dry composition as defined in Item (22)
in which the stabilizer is a hydrophobic amino acid.

10 (24) A dry composition as defined in Items
(11) to (23) in which the particle size is in the range
of from 0.5 μm to 10 μm .

(25) A dry composition as defined in Items (1)
to (23) which is obtained by spray-drying method.

15 (26) A dry composition as defined in Items (11)
to (23) which is obtained by spray-drying method and has
the particle size in the range of from 0.5 μm to 10 μm .

For use as at least one of active ingredients
in the present invention selected from the group
20 consisting of pharmacologically active proteins and
pharmacologically active polypeptides, suitable examples
of such active ingredients include proteins such as
enzyme, hemoglobin, immunoglobulin, hormone, coagulation
factor, etc. and polypeptides including antiviral
25 polypeptides such as interferons- α , - β , - γ and the like,

-9-

immunoregulatory polypeptides such as interleukins 1, 2, 3, 4, 5, 6, 7, 8 and the like, hematopoietic polypeptides, etc. In the present invention, these active ingredients may be used alone or in combination thereof. A variety of peptides can be used in the present invention, which encompass naturally occurring polypeptides, recombinant polypeptides, chemically synthesized polypeptides, and the like.

In the dry composition of the present invention, at least one of hydrophobic stabilizers selected the group consisting of hydrophobic amino acids, hydrophobic dipeptides and hydrophobic tripeptides is included as the stabilizer. In the present invention, it is important to use a hydrophobic stabilizer having a Hydropathy Index ("A Simple Method for Displaying the Hydrophathic Character of a Protein", Jack Kyte and Russel F. Doolittle, J. Mol. Biol., (1982) 157, 105-132) of at least about 3. Examples of suitable hydrophobic amino acids include valine, leucine, isoleucine or the like. Examples of suitable hydrophobic dipeptides include leucyl-valine, isoleucyl-valine, isoleucyl-leucine, phenylalanyl-isoleucine or the like. Examples of suitable hydrophobic tripeptides include isoleucyl-leucyl-valine, isoleucyl-valyl-phenylalanine, isoleucyl-valyl-isoleucine or the like.

-10-

Preferred hydrophobic stabilizers for use in the present invention are those having a Hydropathy Index of at least about 3, preferably of about 3.8 or more, more preferably in the range of from about 3.8 to about 4.5. Specific examples of hydrophobic stabilizers are hydrophobic amino acids, such as valine, leucine, isoleucine or the like. In the present invention, these hydrophobic amino acids may be used alone or in combination thereof.

10 The hydrophobic stabilizer is included in the dry composition of the present invention generally in an amount of, but not specifically limited to, from 40 wt% (inclusive) to 100 wt% (exclusive), in some case from 50 wt% (inclusive) to 100 wt% (exclusive), in some case from 15 60 wt% (inclusive) to 100 wt% (exclusive), and in some case from 70 wt% (inclusive) to 100 wt% (exclusive). Depending on the kind of the active ingredient used, the amount of the hydrophobic stabilizer present in the dry composition of the present invention is, in some case, 20 from 80 wt% (inclusive) to 100 wt% (exclusive).

The amount of the active ingredient contained in the dry composition of the present invention may vary depending on the kind of the active ingredient used and is not generally mentioned. Preferably, the active 25 ingredient is present in the dry composition in an amount

-11-

of 50 wt% or less, in some case 15 wt% or less, in some case 10 wt% or less, and in some case 5 wt% or less.

Even if the same kind of the active ingredient is used, the amount included in the composition may vary,

5 depending on the disease to be treated or the formulations, and a clinically adequate amount of the active ingredient may suitably be included in the dry composition of the present invention. For example, when interferon or interleukin is employed, the suitable
10 amount thereof in the dry composition is 1 to 10×10^7 IU/mg, in some case 10 to 8×10^7 IU/mg, in some case 100 to 6×10^7 IU/mg, in some case 100 to 4×10^7 IU/mg, in some case 100 to 3×10^7 IU/mg, in some case 100 to 2×10^7 IU/mg, and in some case 100 to 1×10^7 IU/mg.

15 In the present invention, in order to stabilize the composition before drying, to stabilize the particulate product after drying, or to prevent absorption to containers, there may suitably be added, before or after drying, known stabilizers including human
20 serum albumin, saccharides such as sucrose, mannitol, trehalose, maltose or the like, amino acids (excluding hydrophobic amino acids) such as glycine, alanine, sodium glutamate or the like, gelatine, and surfactants such as polyoxyethylene sorbitan fatty acid esters, sorbitan
25 trioleate, oleyl alcohol, lecithin or the like.

-12-

When human serum albumin is used, the amount added is generally in the range of from 0 wt% to 20 wt%, in some case from 0 wt% to 30 wt%, in some case from 0 wt% to 40 wt%, in some case from 0 wt% to 50 wt%, and in
5 some case from 0 wt% to 60 wt%.

When human serum albumin is not used, it is preferred to add at least one of known stabilizers such as saccharides, e.g., sucrose, mannitol, trehalose, maltose, etc., amino acids (excluding hydrophobic amino
10 acids), e.g., glycine, alanine, sodium glutamate, etc., gelatine, and surfactants, e.g., polyoxyethylene sorbitan fatty acid esters, sorbitan trioleate, oleyl alcohol, lecithin, etc. Preferably, the saccharides, amino acids and surfactants described above are employed in
15 combination.

When the dry composition of the present invention is formulated into pharmaceutical preparations such as, but not limited to, inhalants, the dry composition is subjected to the following procedure.

20 When employing lyophilization method, a raw material in the form of a solution comprising at least one of active ingredients selected from the group consisting of pharmacologically active proteins and pharmacologically active polypeptides in combination with
25 the hydrophobic stabilizer is subjected to lyophilization

-13-

and the resultant lyophilized product is micronized using a jet-milling equipment, ball-milling equipment or the like.

When employing spray-drying method, a raw material in the form of a solution comprising at least one of active ingredients selected from the group consisting of pharmacologically active proteins and pharmacologically active polypeptides in combination with the hydrophobic stabilizer is spray-dried to produce particles.

Preferred methods for producing the dry composition of the present invention are illustrated below.

The active ingredient and the hydrophobic stabilizer described above are dissolved in water or a mixture of water and lower alcohol. Water can be used singly, but it is preferred to use a mixture of water and lower alcohol in the present invention. Preferred examples of lower alcohols employed in the present invention are alcohols compatible with water, such as, methanol, ethanol, 1-propanol, 2-propanol, butanol, tertiary butanol, etc. The lower alcohol is used alone, but two or more kinds thereof may be used in combination. Of the lower alcohols listed above, ethanol is particularly preferred.

-14-

The suitable mixing ratios of water and lower alcohol employed in the present invention are indicated as follows. The weight ratio of the former to the latter is 40 to 95 : 60 to 5, preferably 40 to 80 : 60 to 20, more preferably 60 to 80 : 40 to 20, and most preferably 60 to 70 : 40 to 30. When the mixing proportion of lower alcohol is less than the above range, it is difficult to efficiently produce dry particles having a particle size of 5.0 μm or less. By contrast, when the mixing proportion of lower alcohol is greater than the above range, it is difficult to dissolve the active ingredient in the above-described mixture and turbidity occurs, and consequently, the pharmaceutically active protein or the like contained in the raw material loses its activity.

In the subsequent step of the method of the present invention, the raw material in the form of a solution comprising the active ingredient and the hydrophobic stabilizer is sprayed into a hot air-stream and dried. The media of the hot air-stream are those that contain inert gas such as nitrogen or the like. In the present invention, the air is preferably used. The conditions in which the raw material is sprayed into a hot air-stream are not critical, but preferably spraying is carried out under the conditions of: spraying pressure of 0.5 to 10 kg/cm^2 , preferably 1 to 3 kg/cm^2 ; spraying

-15-

concentration of 1 to 100 g/min, preferably 5 to 20 g/min; and spray nozzle diameter indicated as an orifice diameter of 50 to 2000 μm , preferably 200 to 1000 μm .

In the present invention, the temperature at which spray-drying is efficiently conducted is normally in the range between about 100°C and about 300°C, preferably between about 120°C and about 180 °C. The moisture content of the particles after spray-drying is 5 % or less, preferably 2 % or less.

In the present invention, a surfactant may be added, before or after spray-drying, to the composition so that dispersability of the resultant particles is improved. A variety of known surfactants can be used, such as, polyoxyethylene sorbitan fatty acid ester, sorbitan trioleate, oleyl alcohol, lecithin or the like.

According to the method of the present invention described above, the dry composition can readily be micronized.

When the dry composition of the present invention is formulated into an inhalant, the particle size of the final granular product is preferably in the range of from 0.1 μm to 10 μm , more preferably in the range of from 0.5 μm to 10 μm .

Brief Description of Drawings

Figure 1 is a graph showing the particle size

-16-

distribution of the dry composition in the form of particles produced by using isoleucine as the amino acid.

Figure 2 is a graph showing the particle size distribution of the dry composition in the form of particles produced by using alanine as the amino acid.

Figure 3 is a graph showing the particle size distribution of the dry composition in the form of particles produced by using proline as the amino acid.

Best Mode for Carrying Out the Invention

The present invention is further described by reference to the following examples.

Example 1

A suitable amount of distilled water for injection was poured into respective vials to give 1 ml of an injection comprising 0.1 ml of a drug substance in solution containing interferon- α (hereinafter referred to as "IFN- α bulk solution", titer: 2×10^7 IU/ml), 5 mg of various amino acids and 1 mg of human serum albumin (HSA) per vial and subjected to lyophilization. Those samples were left to stand for three days under the conditions where the temperature was 40°C, relative humidity (RH) was 75% and the vials were left open (uncapped). Three days after, the titer of IFN- α was determined and the residual activity of INF- α was calculated by setting the IFN- α activity measured after drying to equal 100%.

-17-

Further, the same samples were evaluated for change in appearance after three days of standing under the conditions where the temperature was 40°C, RH was 75% and the vials were open. The results are shown in Table 1 below.

Table 1

	Hydro- pathy Index	Initial IFN- α Activity (%)	Residual IFN- α Activity at 40°C, RH 75%, 3 days after(%)	Change in Appearance
Isoleucine	4.5	100	84.3	No Change
Valine	4.2	100	79.5	No Change
Leucine	3.8	100	77.6	No Change
Phenyl- alanine	2.8	100	61.9	No Change
Alanine	1.9	100	34.9	Slightly Deliquesced
Glycine	-0.4	100	69.2	Almost Deliquesced
Proline	-1.6	100	51.3	Completely Deliquesced
Arginine	-4.5	100	48.8	Completely Deliquesced

As is evident from the results summarized in Table 1, the products obtained by the present invention employing the hydrophobic amino acids having a Hydropathy Index of 3 or greater are remarkably superior in

-18-

stability of IFN- α and/or change in appearance to the products in which other amino acids were employed, even when left in an excessively humid environment.

Example 2

5 (1) Spray-dried products containing IFN- α and isoleucine

Deionized water was added to a mixture of 50 ml of an IFN- α bulk solution (titer: 2×10^7 IU/ml), 3500 mg of isoleucine and 700 mg of HSA, and then stirred thoroughly, to prepare 700 g of an IFN- α solution. To
10 700 g of this IFN- α solution was added 300 g of ethanol to give a weight ratio of water to ethanol of 7 : 3, and the solution to be spray-dried was produced.

Using a spray drier (Yamato Pulvis Basic Unit Model GB-21, manufactured by Yamato Science Co., Ltd.)
15 under the conditions of air-supplying temperature of 130°C, spraying pressure of 2 kg/cm² and spraying rate of 10 g/min, the above solution was spray-dried to produce dry particles.

(2) Spray-dried product containing isoleucine but not
20 containing IFN- α for use as a placebo

Dry particles were produced in the similar manner as in (1) above with the exception that IFN- α was not employed.

The dry particles produced by the processes (1)
25 and (2) above were each evaluated for aerodynamic average

-19-

particle size (volume basis distribution), and the results are shown in Table 2 below. Aerodynamic average particle size was determined by dispersing the particles using an aerodisperser (Amherst Process Instruments, Inc.) and the measurement was conducted by using an aerosizer (Amherst Process Instruments, Inc.). Measuring conditions are as follows: air-stream shearing force: medium; sample particles supplying rate: medium; deagglomeration: normal; and vibration of dispersing pin: on.

Table 2

	Aerodynamic Average Particle Size (μm)
Isoleucine (placebo)	0.9697
Isoleucine (IFN)	0.9549

Table 2 demonstrates that IFN- α does not affect the aerodynamic average particle size of the spray-dried products and the particle size distribution of the particles is dependent on the nature of amino acids employed.

Test Example 1

To make a solution containing 0.5 wt% of each amino acid indicated in Table 3 and 0.1 wt% of HSA, suitable amount of deionized water was added to the solution and thoroughly stirred to prepare 700 g of an

-20-

amino acid solution. To 700 g of this solution was added ethanol to give a weight ratio of water to ethanol of 7 : 3, and the solution to be spray-dried was produced.

Using a spray drier (Yamato Pulvis Basic Unit
5 Model GB-21, manufactured by Yamato Science Co., Ltd.)
under the conditions of air-supplying temperature of
130°C, spraying pressure of 2 kg/cm² and spraying rate of
10 g/min, the above solution was spray-dried to produce
the dry particles.

10 The dry particles produced by the above
processes were each evaluated for moisture content
(moisture content immediately after production and
moisture content 24 hours after standing under the
condition of RH 96%) and the average particle size
15 distribution (volume basis distribution), and the results
are summarized in Table 3 below.

Measurement of moisture content: the water contained
in the dry particles were vaporized using Hiranuma auto
moisture vaporizing instrument (LE-24S) and the moisture
20 content was measured by using Hiranuma moisture
microanalyzer (AQ-6).

Measurement of particle size: by using a laser
diffraction scattering particle size distribution
measuring equipment (LEM-24S, manufactured by Seishin
25 Co., Ltd.), the particle size distribution of the dry

-21-

particles (volume basis distribution) was determined.

Measuring conditions were as follows: dispersing nozzle
pressure: 5.0 kg/cm²; refractive index: 1.33.

Table 3

	Hydropathy Index	Initial IFN- α Activity (%)	Residual IFN- α Activity at RH96% 24hrs after(%)	Particle Size Distribution (μ m)		
				x 10	x 50	x 90
Isoleucine	4.5	1.38	13.64	1.2	2.0	3.1
Valine	4.2	1.90	10.18	1.2	1.8	3.1
Leucine	3.8	1.69	12.05	1.1	1.7	3.3
Phenylalanine	2.8	2.34	13.74	1.5	2.7	7.4
Alanine	1.9	3.11	46.27	1.2	2.0	12.2
Glycine	-0.4	2.29	66.73	1.5	3.8	9.2
Proline	-1.6	2.25	217.80	2.7	13.4	34.9
Arginine	-4.5	Spray-dried products cannot be produced.				

-23-

The values shown in Table 3 are cumulative % under sieving. For example, "x 50" indicates a particle size in which the particles of smaller sizes are accumulated to occupy 50% of the volume.

5 The dry particles produced using isoleucine, alanine or proline as the amino acid were evaluated for the particle size distribution by employing the above procedure and the graphs showing individual particle size distribution are represented in Figures 1, 2 and 3,
10 respectively.

As is evident from the results shown in Table 1 and Figures 1, 2 and 3, the spray-dried products produced by using hydrophobic amino acids having a Hydropathy Index of 3.8 or greater are superior to the products
15 obtained by using other amino acids, in moisture absorption even when the products were left in a highly humid environment and/or in uniformity of the particle size distribution.

Example 3

20 Dry particles were produced in the similar manner as in Example 2 with the exception that 300 g of ethanol was not added.

Examples 4 to 7

25 Dry particles were produced in the similar manner as in Example 2 with the exception that leucine,

-24-

valine, leucyl-valine or isoleucyl-valyl-leucine was used in lieu of isoleucine.

Examples 8 to 22

5 Dry particles were produced in the similar manner as in Example 2 with the exception that an IFN- α bulk solution, isoleucine and HSA were employed in the amounts indicated in Table 4.

Table 4

Example	IFN- α (IU)	Isoleucine(mg)	HSA(mg)
10 8	100×10^7	3500	0
9	100×10^7	3500	7
10	100×10^7	3500	70
11	1×10^7	3500	700
12	1×10^7	3500	0
15 13	1×10^7	3500	7
14	1×10^7	3500	70
15	10×10^7	3500	700
16	10×10^7	3500	0
17	10×10^7	3500	7
20 18	10×10^7	3500	70
19	1000×10^7	3500	700
20	1000×10^7	3500	0
21	1000×10^7	3500	7
22	1000×10^7	3500	70

25 Examples 23 to 37

Dry particles were produced in the similar

-25-

manner as in Example 4 with the exception that an IFN- α bulk solution, leucine and HSA were employed in the amounts indicated in Table 5.

Table 5

5	Example	IFN- α (IU)	Leucine(mg)	HSA(mg)
	23	100×10^7	3500	0
	24	100×10^7	3500	7
	25	100×10^7	3500	70
	26	1×10^7	3500	700
10	27	1×10^7	3500	0
	28	1×10^7	3500	7
	29	1×10^7	3500	70
	30	10×10^7	3500	700
	31	10×10^7	3500	0
15	32	10×10^7	3500	7
	33	10×10^7	3500	70
	34	1000×10^7	3500	700
	35	1000×10^7	3500	0
	36	1000×10^7	3500	7
20	37	1000×10^7	3500	70

Example 38

A suitable amount of deionized water was added to a mixture of 50 ml of an IFN- α bulk solution (titer: 2×10^7 IU/ml), 3500 mg of isoleucine and 700 mg of HSA, and stirred thoroughly, to prepare 700 ml of an IFN- α solution. This solution was lyophilized, and the

-26-

resultant lyophilized product was collected and milled using a jet-milling equipment to obtain dry particles.

Examples 39 to 53

5 Dry particles were produced in the similar manner as in Example 38 with the exception that an IFN- α bulk solution, isoleucine and HSA were employed in the amounts indicated in Table 6.

Table 6

Example	IFN- α (IU)	Isoleucine(mg)	HSA(mg)
10 39	100×10^7	3500	0
40	100×10^7	3500	7
41	100×10^7	3500	70
42	1×10^7	3500	700
43	1×10^7	3500	0
15 44	1×10^7	3500	7
45	1×10^7	3500	70
46	10×10^7	3500	700
47	10×10^7	3500	0
48	10×10^7	3500	7
20 49	10×10^7	3500	70
50	1000×10^7	3500	700
51	1000×10^7	3500	0
52	1000×10^7	3500	7
53	1000×10^7	3500	70

25 Example 54

Dry particles were produced in the similar

-27-

manner as in Example 38 by performing lyophilization with the exception that in lieu of isoleucine, 3500 mg of leucine was used.

Examples 55 to 69

5 Dry particles were produced in the similar manner as in Example 54 with the exception that an IFN- α bulk solution, leucine and HSA were employed in the amounts indicated in Table 7.

Table 7

10	Example	IFN- α (IU)	Leucine(mg)	HSA(mg)
	55	100×10^7	3500	0
	56	100×10^7	3500	7
	57	100×10^7	3500	70
	58	1×10^7	3500	700
15	59	1×10^7	3500	0
	60	1×10^7	3500	7
	61	1×10^7	3500	70
	62	10×10^7	3500	700
	63	10×10^7	3500	0
20	64	10×10^7	3500	7
	65	10×10^7	3500	70
	66	1000×10^7	3500	700
	67	1000×10^7	3500	0
	68	1000×10^7	3500	7
25	69	1000×10^7	3500	70

Example 70

-28-

Dry particles were produced in the similar manner as in Example 2 with the exception that in lieu of the IFN- α bulk solution, 50 ml of an IFN- γ bulk solution (titer: 2×10^7 IU/ml) was used.

5 Example 71

Dry particles were produced in the similar manner as in Example 2 with the exception that in lieu of the IFN- α bulk solution, 50 ml of a bulk solution containing interleukin- 1β in which cysteine at position
10 71 was substituted with serine (described in European Patent Publication No. 237073A; titer: 1.2×10^8 IU/ml) was used.

Example 72

Dry particles were produced in the similar
15 manner as in Example 2 with the exception that in lieu of the IFN- α bulk solution, 50 ml of a bulk solution containing interleukin- 1α in which asparagine at position 36 was substituted with aspartic acid and cysteine at position 141 was substituted with serine (described in
20 European Patent Publication No. 237073A; titer: 1.3×10^8 IU/ml) was used.

Example 73

Dry particles were produced in the similar
manner as in Example 38 with the exception that in lieu
25 of the IFN- α bulk solution, 50 ml of an IFN- γ bulk

-29-

solution (titer: 2×10^7 IU/ml) was used.

Example 74

Dry particles were produced in the similar manner as in Example 38 with the exception that in lieu
5 of the IFN- α bulk solution, 50 ml of a bulk solution containing interleukin- 1β in which cysteine at position 71 was substituted with serine (described in European Patent Publication No. 237073A; titer: 1.2×10^8 IU/ml) was used.

10 Example 75

Dry particles were produced in the similar manner as in Example 38 with the exception that in lieu
of the IFN- α bulk solution, 50 ml of a bulk solution containing interleukin- 1β in which asparagine at position
15 36 was substituted with aspartic acid and cysteine at position 141 was substituted with serine (described in European Patent Publication No. 237073A; titer: 1.2×10^8 IU/ml) was used.

Examples 76 to 91

20 Dry particles were produced in the similar manner as in Example 2 with the exception that the IFN- α bulk solution, hydrophobic stabilizers (leucine and valine) and other stabilizers (glycine, sucrose or mannitol) were employed in the amounts indicated in Table
25 8.

Table 8

Example	IFN- α (IU)	Hydrophobic Stabilizer		Other Stabilizer			
		Leucine(mg)	Valine(mg)	Glycine(mg)	Sucrose(mg)	Mannitol(mg)	
76	1×10^7	3000	500				
77	10×10^7	3000	500				
78	100×10^7	3000	500				
79	1000×10^7	3000	500				
80	1×10^7	2500	500	500			
81	10×10^7	2500	500	500			
82	100×10^7	2500	500	500			
83	1000×10^7	2500	500	500			
84	1×10^7	2500	500		500		
85	10×10^7	2500	500		500		
86	100×10^7	2500	500		500		
87	1000×10^7	2500	500		500		
88	1×10^7	2500	500			500	
89	10×10^7	2500	500			500	
90	100×10^7	2500	500			500	
91	1000×10^7	2500	500			500	

-31-

Examples 92 to 107

Dry particles were produced in the similar manner as in Example 38 with the exception that the IFN- α bulk solution, hydrophobic stabilizers (leucine and valine) and other stabilizers (glycine, sucrose or mannitol) were employed in the amounts indicated in Table 9.

Table 9

Example	IFN- α (IU)	Hydrophobic Stabilizer		Other Stabilizer		
		Leucine(mg)	Valine(mg)	Glycine(mg)	Sucrose(mg)	Mannitol(mg)
92	1×10^7	3000	500			
93	10×10^7	3000	500			
94	100×10^7	3000	500			
95	1000×10^7	3000	500			
96	1×10^7	2500	500	500		
97	10×10^7	2500	500	500		
98	100×10^7	2500	500	500		
99	1000×10^7	2500	500	500		
100	1×10^7	2500	500		500	
101	10×10^7	2500	500		500	
102	100×10^7	2500	500		500	
103	1000×10^7	2500	500		500	
104	1×10^7	2500	500			500
105	10×10^7	2500	500			500
106	100×10^7	2500	500			500
107	1000×10^7	2500	500			500

-33-

CLAIMS

1. A dry composition comprising at least one of active ingredients selected from the group consisting of pharmacologically active proteins and
5 pharmacologically active polypeptides and as a stabilizer at least one of hydrophobic stabilizers selected the group consisting of hydrophobic amino acids, hydrophobic dipeptides and hydrophobic tripeptides having a Hydropathy Index of at least about 3.
- 10 2. A dry composition according to claim 1, wherein the stabilizer is a hydrophobic stabilizer having a Hydropathy Index ranging from about 3.8 to about 4.5.
3. A dry composition according to claim 2, wherein the stabilizer is valine.
- 15 4. A dry composition according to claim 2, wherein the stabilizer is leucine.
5. A dry composition according to claim 2, wherein the stabilizer is isoleucine.
6. A dry composition according to claim 2,
20 wherein the active ingredient is interferon.
7. A dry composition according to claim 6, wherein the stabilizer is a hydrophobic amino acid.
8. A dry composition according to claim 7, wherein the active ingredient is interferon- α .
- 25 9. A dry composition according to claim 2,

-34-

wherein the active ingredient is interleukin.

10. A dry composition according to claim 9,
wherein the stabilizer is a hydrophobic amino acid.

11. A dry composition according to claim 1,
5 wherein the particle size is in the range of from 0.1 μm
to 10 μm .

12. A dry composition according to claim 11,
wherein the stabilizer is a hydrophobic stabilizer having
a Hydropathy Index ranging from about 3.8 to about 4.5.

10 13. A dry composition according to claim 12,
wherein the stabilizer is a hydrophobic amino acid.

14. A dry composition according to claim 13,
wherein the stabilizer is valine.

15 15. A dry composition according to claim 13,
wherein the stabilizer is leucine.

16. A dry composition according to claim 13,
wherein the stabilizer is isoleucine.

17. A dry composition according to claim 12,
wherein the active ingredient is interferon.

20 18. A dry composition according to claim 17,
wherein the stabilizer is a hydrophobic amino acid.

19. A dry composition according to claim 18,
wherein the stabilizer is valine.

25 20. A dry composition according to claim 18,
wherein the stabilizer is leucine.

-35-

21. A dry composition according to claim 18,
wherein the stabilizer is isoleucine.


22. A dry composition according to claim 12,
wherein the active ingredient is interleukin.

5 23. A dry composition according to claim 22,
wherein the stabilizer is a hydrophobic amino acid.

24. A dry composition according to claims 11
to 23, wherein the particle size is in the range of from
0.5 μm to 10 μm .

10 25. A dry composition according to claims 1 to
23 which is obtained by spray-drying method.

26. A dry composition according to claims 11 to
23 which is obtained by spray-drying method and has the
particle size in the range of from 0.5 μm to 10 μm .

Figure 1

2/3

Figure 2





Figure 3

INTERNATIONAL SEARCH REPORT

International Application No
PCT/JP 96/03772

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K47/18

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X Y	EP 0 578 823 A (SUMITOMO PHARMACEUTICALS) 19 January 1994 see claims 1,2 see page 3, line 10 - line 31 ---	1,2,4, 6-10 11-13, 15,17, 18,20, 22-26
X Y	EP 0 437 622 A (KYOWA HAKKO KOGYO) 24 July 1991 see claims 1,5 ---	1-5 11-16, 22-26
P,Y	EP 0 709 085 A (TAKEDA CHEMICAL INDUSTRIES) 1 May 1996 see claims 1,4,5,9,10,13,38,40,41 see page 8, line 6 - line 11 see page 8, line 42 - line 46 -----	11-18, 20,22-26

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *&* document member of the same patent family

Date of the actual completion of the international search

13 May 1997

Date of mailing of the international search report

29.05.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Ventura Amat, A

INTERNATIONAL SEARCH REPORT

Internat Application No
PCT/JP 96/03772

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 578823 A	19-01-94	BR 9205864 A CA 2107473 A WO 9217209 A US 5496559 A	28-06-94 09-10-92 15-10-92 05-03-96

EP 437622 A	24-07-91	JP 3041033 A CA 2035893 A WO 9100739 A	21-02-91 08-01-91 24-01-91

EP 709085 A	01-05-96	CA 2159552 A JP 8151321 A	31-03-96 11-06-96
